CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tango Therapeutics today announced an expansion of its management team with the promotion of Alan Huang, Ph.D., to chief scientific officer and the addition of Charles Davis, Ph.D., as senior vice president, pharmaceutical sciences (DMPK, safety assessment and clinical pharmacology).
The new appointments bolster Tango’s expertise in oncology translational research and clinical pharmacology as the company advances its goal of creating novel, targeted medicines for specific cancer subtypes using the principle of synthetic lethality.
“We are thrilled to have Alan leading our scientific efforts. His wealth of experience in oncology research and his strategic approach to building Tango’s target and drug discovery platform will help us in our drive to get important new drugs to the patients who need them most,” said Barbara Weber, M.D., Tango’s chief executive officer. “I’m also delighted to welcome Charles to lead our pharmaceutical sciences capabilities. His expertise will be vital as we build a fully integrated biopharma company with capabilities from target discovery through clinical development and commercialization.”
Alan Huang, Ph.D., joined Tango Therapeutics as senior vice president, head of biology, after serving as a consultant at Third Rock Ventures, where he played a leading role in the creation and launch of Tango. At Tango, Alan has led the process of designing and building Tango’s novel, CRISPR-based, target discovery platform, and has been instrumental in advancing programs in drug discovery. Before joining Third Rock, Alan worked at the Novartis Institutes for BioMedical Research as senior director and interim global head of oncology translational research. Under his leadership, the group advanced multiple Novartis compounds through development. He began his career at Millennium Pharmaceuticals. Alan earned his B.S. in biochemistry from Fudan University and his doctorate in biochemistry and molecular biology from the University of South Alabama. He is an author on more than 30 peer-reviewed publications and holds nearly 20 patents.
“I’m excited to be expanding my role at Tango at a time when we’ve validated our approach and we’re moving ahead with a clear sense of purpose to produce therapeutic breakthroughs for patients,” Alan said.
Charles Davis, Ph.D., comes to Tango from the Novartis Institutes for BioMedical Research, where he served as vice president, PK sciences. At NIBR, he led an international team of scientists representing the PKS discipline on more than 100 projects and was a member of the PKS Leadership Team, the Integrated Cancer Board and the Oncology Development Leadership Team. Before joining Novartis, Charles spent more than 20 years at GlaxoSmithKline, where he served on the leadership teams of three of GSK's Centers of Excellence in Drug Discovery. Charles has a B.A. in chemistry from Swarthmore College and a Ph.D. in biophysical chemistry from Cornell University.
“Tango’s science is truly exciting,” Charles said. “This is a dynamic team and I’m glad to come aboard as we work together to build on our strong scientific foundation to advance multiple programs to the clinic.”
About Tango Therapeutics
Tango Therapeutics, a 2017 “Fierce 15” company, is a biotechnology company developing novel therapies targeting context-dependent vulnerabilities in cancers. Tango’s robust product engine is designed to support the discovery and development of breakthrough medicines that provide deeper, more sustained benefit than today’s targeted therapies, and that extend the benefits of available immuno-oncology agents. The company’s programs are focused in the area of synthetic lethality, the interaction between two genes that causes cell death when both are inactivated. Tango was launched in 2017 with a $55 million Series A investment funded by Third Rock Ventures. For more information, please visit www.tangotx.com.
